Castle Biosciences, Inc.

As we discussed in Part 1 of this article, pharma is deriving value from applications of digital pathology across the spectrum of drug discovery and development. However, despite its promise, provider

Biopharma Acquisitions Biopharma merger and acquisition value for the second quarter of 2022 reached $25.4bn from 36 transactions, 20 of which had disclosed values. Four M&A transactions hit or exceed

The difference between fundraising by private biopharmaceutical companies and publicly traded drug developers has been stark in 2022. In fact, the last few days of June were emblematic of the long lag

Rejected by US regulators in February, Amryt Pharma 's butterfly skin therapy Filsuvez has been recommended in Europe to the delight of the Irish firm and patients with the rare and devastating hered